Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma
Bone Marrow Transplant
.
2021 Sep;56(9):2280-2283.
doi: 10.1038/s41409-021-01320-y.
Epub 2021 May 7.
Authors
Enrico Derenzini
1
2
,
Valentina Tabanelli
3
,
Simona Sammassimo
4
,
Saveria Mazzara
3
,
Giovanna Motta
3
,
Federica Melle
3
,
Anna Vanazzi
4
,
Angelica Calleri
3
,
Stefano Fiori
3
,
Maria Chiara Finazzi
5
,
Maria Chiara Barbanti
5
,
Safaa Ramadan
4
,
Sara Gandini
6
,
Rocco Pastano
4
,
Alessandro Rambaldi
5
7
,
Stefano Pileri
3
,
Corrado Tarella
8
9
Affiliations
1
Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy. enrico.derenzini@ieo.it.
2
Department of Health Sciences, University of Milan, Milan, Italy. enrico.derenzini@ieo.it.
3
Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
4
Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
5
Hematology and Bone marrow Transplant Unit, ASST-Papa Giovanni XXIII, Bergamo, Italy.
6
Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
7
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
8
Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy. corrado.tarella@ieo.it.
9
Department of Health Sciences, University of Milan, Milan, Italy. corrado.tarella@ieo.it.
PMID:
33963303
DOI:
10.1038/s41409-021-01320-y
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma* / therapy
Neoplasm Recurrence, Local
Stem Cell Transplantation